• Quantifying 1-Methyl Ado by UHPLC–MS/MS

  2026-09-18

  The 2024 Analytical Chemistry study developed a stable isotope-diluted UHPLC–ESI–MS/MS workflow for simultaneous measurement of 12 purine ribonucleosides, including 10 methylated species. Ammonium bicarbonate-enhanced ionization, solid-phase extraction, and chromatographic separation of isomers improved sensitivity and enabled intracellular analysis relevant to RNA modification research and biomarker discovery.

• TCAIM Regulation of OGDH and Mitochondrial Metabolism

  2026-09-18

  Wang et al. identify TCAIM as a mitochondrial DNAJC co-chaperone that selectively binds native OGDH and promotes its reduction through HSPA9 and LONP1. The study establishes mitochondrial proteostasis as a post-translational layer of metabolic control, linking OGDH abundance to carbohydrate catabolism in cells and mice.

• DMXAA (Vadimezan): A Translational Vascular Strategy

  2026-09-17

  DMXAA (Vadimezan) offers a mechanism-rich platform for studying tumor vascular disruption, endothelial apoptosis, VEGFR2 signaling, and translational combination strategies in cancer biology research.

• TPPU: A Soluble Epoxide Hydrolase Inhibitor

  2026-09-17

  TPPU is a potent soluble epoxide hydrolase inhibitor that increases fatty acid epoxide signaling by limiting EET hydrolysis. Its nanomolar human and mouse sEH activity supports inflammatory pain research, while emerging liver–bone findings define a research hypothesis rather than a clinical indication.

• Parthenolide, ROS, and Apoptosis in Lymphoid Malignancies

  2026-09-16

  This study integrated resazurin-based metabolic measurements with flow-cytometric and gene-expression analyses to show that parthenolide reduces viability and promotes oxidative-stress-associated apoptosis across diverse lymphoid malignancy models. Its main practical contribution is a comparative framework linking metabolic suppression to ROS accumulation, glutathione depletion, mitochondrial dysfunction, and cell-line-dependent signaling responses.

• mRNA-Loaded Dendritic Cells in Melanoma

  2026-09-16

  The reference study examined long-term outcomes after complete melanoma metastasis resection followed by autologous dendritic cells electroporated with multiple melanoma-antigen mRNAs. More than six years of follow-up supported the feasibility and tolerability of this adjuvant strategy, while the single-center, non-randomized design means that its encouraging survival estimates require controlled validation.

• Nigericin sodium salt: Practical Assay Guide

  2026-09-15

  Nigericin sodium salt (SKU B7644) is a potassium ionophore for controlled K⁺/H⁺ exchange, supporting studies of ion gradients, cytoplasmic pH, platelet responses, and Pb²⁺ transport. It is intended for research workflows only and should not be presented as a validated treatment for lead intoxication or as a universal reagent for every cell model.

• SR 11302 for AP-1-Driven Cancer Workflows

  2026-09-15

  SR 11302 enables selective AP-1 pathway interrogation across tumor-cell and macrophage assays without relying on retinoid receptor activation. This guide translates evidence from colitis-associated colorectal cancer research into practical dose-finding, reporter, qPCR, flow-cytometry, and troubleshooting workflows.

• Relative and Fractional Viability in Cancer Drug Testing

  2026-09-14

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated metrics capture different combinations of growth inhibition and cell death. Its central implication is practical: cancer drug studies should define the biological endpoint being measured and interpret proliferation arrest, killing, and response timing separately.

• Disodium bicinchoninate for Endothelial Assays

  2026-09-14

  Disodium bicinchoninate provides an aqueous route for protein normalization in endothelial stress workflows without a DMSO or ethanol vehicle. This guide translates an H2O2-induced HUVEC study into practical assay design, reagent preparation, quality controls, and troubleshooting steps for mechanistic cell biology.

• Iptacopan (LNP023): Complement Assay Workflows

  2026-09-13

  Iptacopan (LNP023) gives researchers a selective, reversible way to isolate alternative-pathway biology without broadly suppressing complement. This guide translates its factor B mechanism into practical hemolysis, C3 deposition, serum, and disease-model workflows, with optimization advice for reproducible complement activation research.

• Cyclic di-GMP: Biofilm and STING Workflows

  2026-09-12

  Cyclic di-GMP connects bacterial persistence biology with STING-focused immune modulation research. This practical guide translates its antitoxin and STING agonist roles into biofilm, biochemical, and cancer immunotherapy studies while emphasizing preparation, controls, and troubleshooting.

• Anti Reverse Cap Analog for High-Expression mRNA

  2026-09-11

  Anti Reverse Cap Analog, 3´-O-Me-m7G(5')ppp(5')G, gives in vitro transcription workflows orientation-specific Cap 0 mRNA with approximately twofold higher translation than conventional m7G capping. This article connects cap optimization with LNP delivery, including the IL-10 mRNA strategy used to study poststroke microglia and blood–brain barrier repair.

• Anti Reverse Cap Analog for Synthetic mRNA

  2026-09-11

  Anti Reverse Cap Analog (ARCA) enables orientation-controlled 5′ capping for high-expression synthetic mRNA workflows. Its value is especially clear in transient cell-fate programming, where reliable translation can improve repeated delivery strategies without genomic integration.

• DMXAA (Vadimezan) Workflow for Tumor Models

  2026-09-10

  DMXAA (Vadimezan) supports complementary tumor-cell, endothelial, enzymatic, and formulation-based assays. This workflow connects vascular disruption and VEGFR2-related signaling with a recent nuclear-targeted nanorod strategy that uses DMXAA to amplify DNA damage and STING-associated innate immunity.

8524 records 1/569 page Next 12345 下5页 Last page